Patent Application
Utility
App. No. 17/570,253
· Confirmation No. 1200
FORMULATIONS OF L-ORNITHINE PHENYLACETATE
Applicant:
OCERA THERAPEUTICS, INC.
Abandoned -- Failure to Respond to an Office Action
View Publication ↗
|
⬇ PDF
|
Code | Description | Pages | ||
|---|---|---|---|---|---|
| 2025-08-14 | OATH |
Oath or Declaration filed | 75 | View | |
| 2023-10-26 | ABN |
Abandonment | 2 | View | |
| 2023-04-13 | CTNF |
Non-Final Rejection | 14 | View | |
| 2023-04-13 | 892 |
List of references cited by examiner | 1 | View | |
| 2023-04-13 | SRFW |
Search information including classification, databases and other search related notes | 1 | View | |
| 2023-04-13 | SRNT |
Examiner's search strategy and results | 1 | View | |
| 2023-04-13 | SRNT |
Examiner's search strategy and results | 25 | View | |
| 2023-04-13 | 1449 |
List of References cited by applicant and considered by examiner | 5 | View | |
| 2022-06-30 | NTC.PUB |
Notice of Publication | 1 | View | |
| 2022-03-23 | APP.FILE.REC |
Filing Receipt | 4 | View | |
| 2022-03-23 | WFEE |
Fee Worksheet (SB06) | 1 | View | |
| 2022-03-21 | TRAN.LET |
Transmittal Letter | 1 | View | |
| 2022-03-21 | TRAN.LET |
Transmittal Letter | 1 | View | |
| 2022-03-21 | IDS |
Information Disclosure Statement (IDS) Form (SB08) | 5 | View | |
| 2022-03-21 | A.PE |
Preliminary Amendment | 1 | View | |
| 2022-03-21 | CLM |
Claims | 2 | View | |
| 2022-03-21 | REM |
Applicant Arguments/Remarks Made in an Amendment | 1 | View | |
| 2022-03-21 | WFEE |
Fee Worksheet (SB06) | 2 | View | |
| 2022-03-21 | N417 |
Electronic Filing System Acknowledgment Receipt | 3 | View | |
| 2022-03-21 | FOR |
Foreign Reference | 6 | View | |
| 2022-01-20 | WCLM |
Claims Worksheet (PTO-2022) | 1 | View | |
| 2022-01-20 | APP.FILE.REC |
Filing Receipt | 4 | View | |
| 2022-01-20 | WFEE |
Fee Worksheet (SB06) | 1 | View | |
| 2022-01-20 | NTC.MISS.PRT |
Notice to File Missing Parts | 2 | View | |
| 2022-01-06 | PA.. |
Power of Attorney | 2 | View | |
| 2022-01-06 | DRW |
Drawings-only black and white line drawings | 4 | View | |
| 2022-01-06 | SPEC |
Specification | 23 | View | |
| 2022-01-06 | CLM |
Claims | 4 | View | |
| 2022-01-06 | ABST |
Abstract | 1 | View | |
| 2022-01-06 | OATH |
Oath or Declaration filed | 7 | View | |
| 2022-01-06 | ADS |
Application Data Sheet | 9 | View | |
| 2022-01-06 | N417 |
Electronic Filing System Acknowledgment Receipt | 3 | View |
Inventors
Attorneys & Agents of Record
Classification
USPC
424/494
A61K31/198
A61K9/0053
A61K9/08
A61K9/5026
A61K9/5047
A61K9/5078
A61K31/222
A61K2300/00
Prosecution
- Examiner
- PALLAY, MICHAEL B
- Art Unit
- 1617
- Customer No.
- 20995
- Docket No.
- OCERA.065C1
- Confirmation No.
- 1200
Publication
- Pub. No.
- US20220202755A1
- Pub. Date
- 2022-06-30
Parent
is a Continuation of
→
App. 15/349,910
· US 11,219,611
Filed 2016-11-11
· Patented Case
Parent
is a Continuation in-part of
→
App. 15/133,087
Filed 2016-04-19
· Abandoned -- Failure to Respond to an Office Action
Parent
Claims priority from a provisional application
→
App. 62/276,754
Filed 2016-01-08
· Provisional Application Expired
Parent
Claims priority from a provisional application
→
App. 62/255,300
Filed 2015-11-13
· Provisional Application Expired
MALLINCKRODT ENTERPRISES LLC,
MALLINCKRODT LLC,
MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY,
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED,
OCERA THERAPEUTICS LLC,
SPECGX LLC,
STRATATECH CORPORATION,
SUCAMPO PHARMA AMERICAS LLC,
VTESSE LLC
RELEASE OF SECURITY INTEREST
Recorded 2025-08-14
MALLINCKRODT ENTERPRISES LLC,
MALLINCKRODT LLC,
SPECGX LLC,
OCERA THERAPEUTICS, INC.,
STRATATECH CORPORATION,
VTESSE LLC,
MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY,
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED,
SUCAMPO PHARMA AMERICAS LLC
RELEASE OF SECURITY INTEREST
Recorded 2024-10-07
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded 2024-01-31
MALLINCKRODT ENTERPRISES LLC,
MALLINCKRODT LLC,
SPECGX LLC,
OCERA THERAPEUTICS, INC.,
STRATATECH CORPORATION,
VTESSE LLC,
MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY,
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED,
SUCAMPO PHARMA AMERICAS LLC
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536
Recorded 2023-11-16
OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.),
MALLINCKRODT LLC,
MALLINCKRODT ENTERPRISES LLC,
MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY,
SPECGX LLC,
STRATATECH CORPORATION,
SUCAMPO PHARMA AMERICAS LLC,
VTESSE LLC,
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913
Recorded 2023-11-15
from
MALLINCKRODT ENTERPRISES LLC,
MALLINCKRODT LLC,
MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY,
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED,
OCERA THERAPEUTICS LLC,
SPECGX LLC,
STRATATECH CORPORATION,
SUCAMPO PHARMA AMERICAS LLC,
VTESSE LLC
SECURITY INTEREST
Recorded 2023-11-15
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded 2023-05-12
from
MALLINCKRODT ENTERPRISES LLC,
MALLINCKRODT LLC,
MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY,
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED,
OCERA THERAPEUTICS, INC.,
SPECGX LLC,
STRATATECH CORPORATION,
SUCAMPO PHARMA AMERICAS LLC,
VTESSE LLC
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY
Recorded 2022-06-22
from
MALLINCKRODT ENTERPRISES LLC,
MALLINCKRODT LLC,
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED,
OCERA THERAPEUTICS, INC.,
SPECGX LLC,
STRATATECH CORPORATION,
SUCAMPO PHARMA AMERICAS LLC,
VTESSE LLC
SECURITY INTEREST
Recorded 2022-06-17
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this application's details
Quick Facts
- App. No.
- 17/570,253
- Filed
- 2022-01-06
- Pub. No.
- US20220202755A1
- Examiner
- PALLAY, MICHAEL B
- Art Unit
- 1617
External Links